SEC Form 4 · accession 0001209191-17-059396
Karyopharm Therapeutics Inc. · KPTI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher Brett Primiano
Officer — SVP, OPS, BUS DEV, GC & SEC
Period of report
Nov 5, 2017
Accepted (ET)
Nov 6, 2017 · 4:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001503802
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Nov 5, 2017 | M | 15,000 | — | A | 26,381 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | Nov 5, 2017 | M | 15,000 | D | — | — | Common Stock | 15,000 | 0 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of Karyopharm Therapeutics Inc. common stock.
- F2On November 5, 2015, the reporting person was granted 30,000 restricted stock units. 50% of the restricted stock units vested on November 5, 2016. The remaining 50% of the restricted stock units vested on November 5, 2017. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date.